Blood Bag Market Size, Share, Opportunities, And Trends By Product Type (Single Blood Bag, Double Blood Bag, Triple Blood Bag, Quadruple Blood Bag, Penta Blood Bag), By Capacity (Less than 250 ml, 250 ml - 500 ml, Above 500 ml), By End User (Hospitals, Diagnostic Centres, Clinical Research, Blood Banks ), By Therapeutic Area (Oncology, Autoimmune Diseases, Metabolic Diseases, Cardiovascular Diseases, Neurology, Infectious Diseases, Others), And By Geography - Forecasts From 2024 To 2029

The blood bag market is anticipated to grow significantly over the forecast period.

The blood bag market plays a crucial role in the healthcare industry by providing essential tools for safe and efficient blood collection, storage, and transfusion. These specialized bags are designed to maintain the integrity and sterility of blood components, ensuring optimal patient care during medical procedures such as surgeries, trauma treatments, and chronic disease management.

The increasing demand for blood transfusions, driven by factors such as rising disease prevalence, surgical procedures, and emergency care needs, has driven the blood-bag market to witness steady growth. Advances in technology, such as the development of innovative materials and manufacturing processes, further enhance the safety and efficiency of blood bag systems. Additionally, initiatives aimed at promoting blood donation and improving healthcare infrastructure contribute to the market expansion, ultimately benefiting patients and healthcare providers worldwide.

Market Drivers

• Rising rate of road accidents

Road accidents are anticipated to significantly drive the blood bag market growth, as these incidents often necessitate immediate medical attention, including blood transfusions. The substantial number of road accidents is expected to be a key factor influencing the demand for blood bags. For example, data from the World Health Organization's June 2021 update indicates that approximately 1.3 million individuals lose their lives annually due to road traffic accidents, while 20 to 50 million people sustain non-fatal injuries, many of which result in disabilities. Moreover, despite low- and middle-income countries accounting for 60% of the world's vehicles, they bear the brunt of road accident fatalities, comprising 93% of all deaths related to such incidents. Consequently, the high incidence of road accidents is projected to drive increased demand for blood bags, leading to the anticipated market growth.

• Increasing number of blood cancer patients

The demand for blood bags has surged due to an increasing number of patients afflicted with various blood-related, kidney, metabolic, and neurological disorders. Conditions such as leukemia, lymphoma, myeloma, and myelodysplastic syndromes (MDS) can affect vital components of the body, such as the bone marrow, blood cells, lymph nodes, and the lymphatic system. Apheresis technology has been instrumental in reducing white cell counts until alternative medications can manage them effectively. For instance, data from the Leukemia and Lymphoma Society (LLS) Factsheet in August 2021 revealed that in the United States, an individual is diagnosed with blood cancer approximately every three minutes. Furthermore, in 2021 alone, 186,400 people were diagnosed with leukemia and lymphoma in the United States, with 825,651 individuals living with lymphoma, 152,671 with Hodgkin lymphoma, and 672,980 with non-Hodgkin lymphoma. This rising prevalence of blood cancers is contributing significantly to the targeted market expansion.

North America is anticipated to hold a significant share of the market-

The blood bag market in North America has seen significant growth attributed to heightened blood transfusion rates, an uptick in disease prevalence, increased public awareness, and extensive blood donation campaigns by both private and government entities. This growing demand for blood bags is a key driver of market expansion. For instance, as estimated by the American National Red Cross in February 2021, the United States requires around 36,000 units of red blood cells daily, with approximately 21 million blood components transfused annually. This escalating demand is fueling market growth. Moreover, according to the Globocan 2020 report, Canada recorded 8,506 cases of non-Hodgkin lymphoma, contributing to the need for blood bags in the region.

Furthermore, the market growth is spurred by an increase in road accidents and the rising prevalence of chronic illnesses. For instance, data from the American Red Cross in March 2021 indicated that a single car accident victim may necessitate up to 100 units of blood. This trend is anticipated to boost the demand for blood transfusions in the foreseeable future.

Market Developments

• In April 2022, Terumo Blood and Cell Technologies secured a contract worth USD 10.6 million to further its efforts in developing freeze-dried plasma (FDP). The contract was awarded by MTEC, the Medical Technology Enterprise Consortium, a biomedical technology consortium operating under an Other Transaction Agreement (OTA) with the United States. The Army Medical Research and Development Command sponsors MTEC, which is managed by the Naval Medical Research Center (NMRC) to advance healthcare solutions for military personnel on the battlefield, under the oversight of the Defense Health Agency (DHA).
• In April 2022, the American Oncology Institute inaugurated a new blood bank center at Babina Specialty Hospital in Imphal East, India. This center offers its services to private hospitals as well as bedridden patients receiving home care.

Market Segmentation

• By Product Type
  • Single Blood Bag
  • Double Blood Bag
  • Triple Blood Bag
  • Quadruple Blood Bag
  • Penta Blood Bag
• By Capacity
  • Less than 250 ml
  • 250 ml - 500 ml
  • Above 500 ml
• By End User
  • Hospitals
  • Diagnostic Centres
  • Clinical Research
  • Blood Banks
• By Therapeutic Area
  • Oncology
  • Autoimmune Diseases
  • Metabolic Diseases
  • Cardiovascular Diseases
  • Neurology
  • Infectious Diseases
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Others

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Processes

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. BLOOD BAG MARKET BY PRODUCT TYPE

5.1. Introduction

5.2. Single Blood Bag

5.2.1. Market Opportunities and Trends

5.2.2. Growth Prospects

5.3. Double Blood Bag

5.3.1. Market Opportunities and Trends

5.3.2. Growth Prospects

5.4. Triple Blood Bag

5.4.1. Market Opportunities and Trends

5.4.2. Growth Prospects

5.5. Quadruple Blood Bag

5.5.1. Market Opportunities and Trends

5.5.2. Growth Prospects

5.6. Penta Blood Bag

5.6.1. Market Opportunities and Trends

5.6.2. Growth Prospects

6. BLOOD BAG MARKET BY CAPACITY

6.1. Introduction

6.2. Less than 250 ml

6.2.1. Market Opportunities and Trends

6.2.2. Growth Prospects

6.3. 250 ml - 500 ml

6.3.1. Market Opportunities and Trends

6.3.2. Growth Prospects

6.4. Above 500 ml

6.4.1. Market Opportunities and Trends

6.4.2. Growth Prospects

7. BLOOD BAG MARKET BY END-USER

7.1. Introduction

7.2. Hospitals

7.2.1. Market Opportunities and Trends

7.2.2. Growth Prospects

7.3. Diagnostic Centres

7.3.1. Market Opportunities and Trends

7.3.2. Growth Prospects

7.4. Clinical Research

7.4.1. Market Opportunities and Trends

7.4.2. Growth Prospects

7.5. Blood Banks

7.5.1. Market Opportunities and Trends

7.5.2. Growth Prospects

8. BLOOD BAG MARKET BY THERAPEUTIC AREA

8.1. Introduction

8.2. Oncology

8.2.1. Market Opportunities and Trends

8.2.2. Growth Prospects

8.3. Autoimmune Diseases

8.3.1. Market Opportunities and Trends

8.3.2. Growth Prospects

8.4. Metabolic Diseases

8.4.1. Market Opportunities and Trends

8.4.2. Growth Prospects

8.5. Cardiovascular Diseases

8.5.1. Market Opportunities and Trends

8.5.2. Growth Prospects

8.6. Neurology

8.6.1. Market Opportunities and Trends

8.6.2. Growth Prospects

8.7. Infectious Diseases

8.7.1. Market Opportunities and Trends

8.7.2. Growth Prospects

8.8. Others

8.8.1. Market Opportunities and Trends

8.8.2. Growth Prospects

9. BLOOD BAG MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. By Product Type

9.2.2. By Capacity

9.2.3. By End User

9.2.4. By Therapeutic Area

9.2.5. By Country

9.2.5.1. United States

9.2.5.1.1. Market Opportunities and Trends

9.2.5.1.2. Growth Prospects

9.2.5.2. Canada

9.2.5.2.1. Market Opportunities and Trends

9.2.5.2.2. Growth Prospects

9.2.5.3. Mexico

9.2.5.3.1. Market Opportunities and Trends

9.2.5.3.2. Growth Prospects

9.3. South America

9.3.1. By Product Type

9.3.2. By Capacity

9.3.3. By End User

9.3.4. By Therapeutic Area

9.3.5. By Country 

9.3.5.1. Brazil

9.3.5.1.1. Market Opportunities and Trends

9.3.5.1.2. Growth Prospects

9.3.5.2. Argentina

9.3.5.2.1. Market Opportunities and Trends

9.3.5.2.2. Growth Prospects

9.3.5.3. Others

9.3.5.3.1. Market Opportunities and Trends

9.3.5.3.2. Growth Prospects

9.4. Europe

9.4.1. By Product Type

9.4.2. By Capacity

9.4.3. By End User

9.4.4. By Therapeutic Area

9.4.5. By Country

9.4.5.1. United Kingdom

9.4.5.1.1. Market Opportunities and Trends

9.4.5.1.2. Growth Prospects

9.4.5.2. Germany

9.4.5.2.1. Market Opportunities and Trends

9.4.5.2.2. Growth Prospects

9.4.5.3. France

9.4.5.3.1. Market Opportunities and Trends

9.4.5.3.2. Growth Prospects

9.4.5.4. Italy

9.4.5.4.1. Market Opportunities and Trends

9.4.5.4.2. Growth Prospects

9.4.5.5. Spain

9.4.5.5.1. Market Opportunities and Trends

9.4.5.5.2. Growth Prospects

9.4.5.6. Others

9.4.5.6.1. Market Opportunities and Trends

9.4.5.6.2. Growth Prospects

9.5. Middle East and Africa

9.5.1. By Product Type

9.5.2. By Capacity

9.5.3. By End User

9.5.4. By Therapeutic Area

9.5.5. By Country

9.5.5.1. Saudi Arabia

9.5.5.1.1. Market Opportunities and Trends

9.5.5.1.2. Growth Prospects

9.5.5.2. UAE

9.5.5.2.1. Market Opportunities and Trends

9.5.5.2.2. Growth Prospects

9.5.5.3. Others

9.5.5.3.1. Market Opportunities and Trends

9.5.5.3.2. Growth Prospects

9.6. Asia Pacific

9.6.1. By Product Type

9.6.2. By Capacity

9.6.3. By End User

9.6.4. By Therapeutic Area

9.6.5. By Country

9.6.5.1. Japan

9.6.5.1.1. Market Opportunities and Trends

9.6.5.1.2. Growth Prospects

9.6.5.2. China

9.6.5.2.1. Market Opportunities and Trends

9.6.5.2.2. Growth Prospects

9.6.5.3. India

9.6.5.3.1. Market Opportunities and Trends

9.6.5.3.2. Growth Prospects

9.6.5.4. South Korea

9.6.5.4.1. Market Opportunities and Trends

9.6.5.4.2. Growth Prospects

9.6.5.5. Taiwan

9.6.5.5.1. Market Opportunities and Trends

9.6.5.5.2. Growth Prospects

9.6.5.6. Thailand

9.6.5.6.1. Market Opportunities and Trends

9.6.5.6.2. Growth Prospects

9.6.5.7. Indonesia

9.6.5.7.1. Market Opportunities and Trends

9.6.5.7.2. Growth Prospects

9.6.5.8. Others

9.6.5.8.1. Market Opportunities and Trends

9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Haemonetics Corporation

11.2. Terumo Blood and Cell Technologies

11.3. Macopharma USA

11.4. Fresnuise Kabi India Pvt., Ltd

11.5. Qingdao Sinoland International Trade Co.

11.6. Genesis BPS, BL Lifesciences

11.7. Mitra Industries Pvt. Ltd.

11.8. Suru International Pvt. Ltd.

11.9. B. Braun Melsungen AG (Germany)

11.10. HLL Lifecare Limited

11.11. Wego Group

11.12. Polymedicure Limited

Haemonetics Corporation

Terumo Blood and Cell Technologies

Macopharma USA

Fresnuise Kabi India Pvt., Ltd

Qingdao Sinoland International Trade Co.

Genesis BPS, BL Lifesciences

Mitra Industries Pvt. Ltd.

Suru International Pvt. Ltd.

B. Braun Melsungen AG (Germany)

HLL Lifecare Limited

Wego Group

Polymedicure Limited